Michael DiBiasio-White, Ph.D

Michael DiBiasio-White, Ph.D has extensive work experience in the field of biotechnology. From 2011-2013 they were a Research Assistant at Purdue University, where they studied Molecular and Structural Virology. From 2012-2013 they were a Postgraduate Fellow in the Department of Microbial Pathogenesis at Yale University School of Medicine, where they generated molecular reagents and designed trans-expressing virus systems. From 2011-2012 they were a Biology Contractor at Constellation Pharmaceuticals, where they were responsible for purifying protein targets to be used in validation assays of drug functionalities. From 2018-2019 they were a Post Doctoral Fellow at MedImmune, specializing in technology and process development for both upstream and downstream groups in a cross functional manner for the production, purification process development and analytical/biophysical evaluation of vector products. From 2019-2020 they were a Senior Scientist at Ring Therapeutics, where they were the Team Leader for Vector Innovation and was focused on developing and optimizing vector plasmid designs and production conditions. From 2019-2020 they were an Independent Consultant and from 2020-present they have been the Head of New Technologies and Innovation (Viral Vectors/Process) at Affinia Therapeutics, where they are responsible for search and evaluation of new technologies, competitive intelligence and landscape analysis, and directing a team derived of direct and matrix reports.

Michael DiBiasio-White, Ph.D. obtained their Bs in Biology from the University of Massachusetts Dartmouth between 2006 and 2010. Michael then obtained their Master's degree in Cell/Cellular and Molecular Biology from Quinnipiac University between 2012 and 2013. Finally, they obtained their Doctor of Philosophy (PhD) in Molecular Virology from Purdue University between 2013 and 2018. Michael also obtained an Advanced Business Development certification from the EBD Academy in March 2022.